Peter N Van Buren1, Julia B Lewis2, Jamie P Dwyer2, Tom Greene3, John Middleton4, Mohammed Sika2, Kausik Umanath5, Josephine D Abraham3, Shahabul S Arfeen6, Isai G Bowline7, Gil Chernin8, Stephen Z Fadem9, Simin Goral10, Mark Koury2, Marvin V Sinsakul11, Daniel E Weiner12. 1. University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: peter.vanburen@utsouthwestern.edu. 2. Vanderbilt University Medical Center, Nashville, TN. 3. University of Utah Medical Center, Salt Lake City, UT. 4. Duke University Medical Center, Durham, NC. 5. Henry Ford Medical Center, Detroit, MI. 6. Nephrology Specialists PC, Michigan City, IN. 7. Wake Forest University Medical Center, Winston-Salem, NC. 8. Ichilov Medical Center, Tel Aviv, Israel. 9. Kidney Associates PLLC, Houston, TX. 10. University of Pennsylvania Medical Center, Philadelphia, PA. 11. Rush University Medical Center, Chicago, IL. 12. Tufts Medical Center, Boston, MA.
Abstract
BACKGROUND:Phosphate binders are the cornerstone of hyperphosphatemia management in dialysis patients. Ferric citrate is an iron-based oral phosphate binder that effectively lowers serum phosphorus levels. STUDY DESIGN: 52-week, open-label, phase 3, randomized, controlled trial for safety-profile assessment. SETTING & PARTICIPANTS: Maintenance dialysis patients with serum phosphorus levels ≥6.0 mg/dL after washout of prior phosphate binders. INTERVENTION: 2:1 randomization to ferric citrate or active control (sevelamer carbonate and/or calcium acetate). OUTCOMES: Changes in mineral bone disease, protein-energy wasting/inflammation, and occurrence of adverse events after 1 year. MEASUREMENTS: Serum calcium, intact parathyroid hormone, phosphorus, aluminum, white blood cell count, percentage of lymphocytes, serum urea nitrogen, and bicarbonate. RESULTS: There were 292 participants randomly assigned toferric citrate, and 149, to active control. Groups were well matched. For mean changes from baseline, phosphorus levels decreased similarly in the ferric citrate and active control groups (-2.04±1.99 [SD] vs -2.18±2.25 mg/dL, respectively; P=0.9); serum calcium levels increased similarly in the ferric citrate and active control groups (0.22±0.90 vs 0.31±0.95 mg/dL; P=0.2). Hypercalcemia occurred in 4 participants receiving calcium acetate. Parathyroid hormone levels decreased similarly in the ferric citrate and active control groups (-167.1±399.8 vs -152.7±392.1 pg/mL; P=0.8). Serum albumin, bicarbonate, serum urea nitrogen, white blood cell count and percentage of lymphocytes, and aluminum values were similar between ferric citrate and active control. Total and low-density lipoprotein cholesterol levels were lower in participants receiving sevelamer than those receiving ferric citrate and calcium acetate. Fewer participants randomly assigned to ferric citrate had serious adverse events compared with active control. LIMITATIONS: Open-label study, few peritoneal dialysis patients. CONCLUSIONS:Ferric citrate was associated with similar phosphorus control compared to active control, with similar effects on markers of bone and mineral metabolism in dialysis patients. There was no evidence of protein-energy wasting/inflammation or aluminum toxicity, and fewer participants randomly assigned to ferric citrate had serious adverse events. Ferric citrate is an effective phosphate binder with a safety profile comparable to sevelamer and calcium acetate.
RCT Entities:
BACKGROUND:Phosphate binders are the cornerstone of hyperphosphatemia management in dialysis patients. Ferric citrate is an iron-based oral phosphate binder that effectively lowers serum phosphorus levels. STUDY DESIGN: 52-week, open-label, phase 3, randomized, controlled trial for safety-profile assessment. SETTING & PARTICIPANTS: Maintenance dialysis patients with serum phosphorus levels ≥6.0 mg/dL after washout of prior phosphate binders. INTERVENTION: 2:1 randomization to ferric citrate or active control (sevelamer carbonate and/or calcium acetate). OUTCOMES: Changes in mineral bone disease, protein-energy wasting/inflammation, and occurrence of adverse events after 1 year. MEASUREMENTS: Serum calcium, intact parathyroid hormone, phosphorus, aluminum, white blood cell count, percentage of lymphocytes, serum ureanitrogen, and bicarbonate. RESULTS: There were 292 participants randomly assigned to ferric citrate, and 149, to active control. Groups were well matched. For mean changes from baseline, phosphorus levels decreased similarly in the ferric citrate and active control groups (-2.04±1.99 [SD] vs -2.18±2.25 mg/dL, respectively; P=0.9); serum calcium levels increased similarly in the ferric citrate and active control groups (0.22±0.90 vs 0.31±0.95 mg/dL; P=0.2). Hypercalcemia occurred in 4 participants receiving calcium acetate. Parathyroid hormone levels decreased similarly in the ferric citrate and active control groups (-167.1±399.8 vs -152.7±392.1 pg/mL; P=0.8). Serum albumin, bicarbonate, serum ureanitrogen, white blood cell count and percentage of lymphocytes, and aluminum values were similar between ferric citrate and active control. Total and low-density lipoprotein cholesterol levels were lower in participants receiving sevelamer than those receiving ferric citrate and calcium acetate. Fewer participants randomly assigned to ferric citrate had serious adverse events compared with active control. LIMITATIONS: Open-label study, few peritoneal dialysis patients. CONCLUSIONS:Ferric citrate was associated with similar phosphorus control compared to active control, with similar effects on markers of bone and mineral metabolism in dialysis patients. There was no evidence of protein-energy wasting/inflammation or aluminumtoxicity, and fewer participants randomly assigned to ferric citrate had serious adverse events. Ferric citrate is an effective phosphate binder with a safety profile comparable to sevelamer and calcium acetate.
Authors: Douglas S Fuller; Ronald L Pisoni; Brian A Bieber; Friedrich K Port; Bruce M Robinson Journal: Am J Kidney Dis Date: 2013-10-17 Impact factor: 8.860
Authors: Julia B Lewis; Mohammed Sika; Mark J Koury; Peale Chuang; Gerald Schulman; Mark T Smith; Frederick C Whittier; Douglas R Linfert; Claude M Galphin; Balaji P Athreya; A Kaldun Kaldun Nossuli; Ingrid J Chang; Samuel S Blumenthal; John Manley; Steven Zeig; Kotagal S Kant; Juan Jose Olivero; Tom Greene; Jamie P Dwyer Journal: J Am Soc Nephrol Date: 2014-07-24 Impact factor: 10.121
Authors: Kausik Umanath; Mohammed Sika; Robert Niecestro; Carolyn Connelly; Gerald Schulman; Mark J Koury; Julia B Lewis; Jamie P Dwyer Journal: Hemodial Int Date: 2012-06-15 Impact factor: 1.812
Authors: Roger Rodby; Kausik Umanath; Robert Niecestro; James H Jackson; Mohammed Sika; Julia B Lewis; Jamie P Dwyer Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2014-12-13 Impact factor: 2.217
Authors: Marvin Sinsakul; Mohammed Sika; Mark Koury; Warren Shapiro; Tom Greene; Jamie Dwyer; Mark Smith; Stephen Korbet; Julia Lewis Journal: Nephron Clin Pract Date: 2012-10-16
Authors: Annabel Biruete; Kathleen M Hill Gallant; Stephen R Lindemann; Gretchen N Wiese; Neal X Chen; Sharon M Moe Journal: J Ren Nutr Date: 2019-03-04 Impact factor: 3.655
Authors: Annabel Biruete; Corinne E Metzger; Neal X Chen; Elizabeth A Swallow; Curtis Vrabec; Erica L Clinkenbeard; Alexander J Stacy; Shruthi Srinivasan; Kalisha O'Neill; Keith G Avin; Matthew R Allen; Sharon M Moe Journal: Nephrol Dial Transplant Date: 2022-09-22 Impact factor: 7.186